Sprinklr, Inc. ( CXM ) shares are falling after the company reported its first-quarter financial results and appointed a new co-CEO Wednesday. Here's a look at the key figures from the report. 

The Details: Sprinklr ( CXM ) reported quarterly earnings of 9 cents per share which beat the analyst consensus estimate of 7 cents by 28.57% and is a 50% increase over earnings from the same period last year.

Quarterly sales came in at $195.958 million which beat the analyst consensus estimate of $194.371 million and represents a 13.03% increase over sales of $173.363 million from the same period last year. Subscription revenue for the first quarter was $177.4 million, up from $157.7 million one year ago, an increase of 12% year-over-year.

The company also announced the appointment of Trac Pham as co-CEO, effective immediately. Pham will continue as a member of Sprinklr’s board and is standing for reelection at Sprinklr’s 2024 annual meeting of stockholders.

“Despite operating in a more challenging macro environment, we generated strong free cash flow in Q1 and we’re innovating with new products and AI features. While the changes and initiatives we’re implementing will take several quarters to work through, we believe we have the right strategy and leaders in place. We believe that the appointment of Trac Pham as co-CEO will enable us to seamlessly combine our technical innovation with operational leadership,” said Ragy Thomas, Sprinklr ( CXM ) founder and co-CEO.

Outlook: Sprinklr ( CXM ) cut its fiscal year 2025 total revenue outlook from between $804.5 million and $805.5 million to between $779 million and $781 million, versus the consensus estimate of $805.088 million. The company raised its adjusted earnings per share outlook from between 38 and 39 cents per share to between 40 cents and 41 cents per share, versus the 38 cent estimate.

CXM Price Action: According to Benzinga Pro, Sprinklr ( CXM ) shares are down 20.20% after-hours at $8.65 at the time of publication Wednesday.

Related News: What’s Going On With Novavax Stock?